Ankit K. Desai

Sustained immune tolerance induction in enzyme replacement therapy–treated CRIM-negative patients with infantile Pompe disease

Zoheb B. Kazi, Ankit K. Desai, Kathryn L. Berrier et al. · JCI Insight · 2017 · 71 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction

Cindy Li, Ankit K. Desai, Punita Gupta et al. · Genetics in Medicine · 2021 · 57 citations · Full text

Medicine, Immunology, Pediatrics +16

Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy

Ankit K. Desai, Zoheb B. Kazi, Deeksha Bali et al. · Molecular Genetics and Metabolism Reports · 2019 · 43 citations · Full text

Life Sciences, Immunology, Pediatrics +15

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

Ankit K. Desai, Carolyn Baloh, John W. Sleasman et al. · Frontiers in Immunology · 2020 · 41 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T > G “late-onset” GAA variant

Mugdha Rairikar, Laura E. Case, Lauren A. Bailey et al. · Molecular Genetics and Metabolism · 2017 · 34 citations · Full text

Medicine, Child Health, Pediatrics +8